COR2ED - Oncology Medical Conversation
Episodes
Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification
17 Dec 2025
Contributed by Lukas
Understanding HER2-low and HER2-ultralow classification in mBC In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a p...
Understanding EP-NEC: Through Diagnosis, Treatment, and Support
07 Nov 2025
Contributed by Lukas
In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neu...
Exploring the role of targeted radiopharmaceutical treatment in NETs
30 Sep 2025
Contributed by Lukas
How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key...
Tackling mPDAC: chemotherapy strategies that matter
19 May 2025
Contributed by Lukas
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, sur...
Understanding Rare NSCLC Mutations: Insights, access and support
14 May 2025
Contributed by Lukas
Listen to a revealing conversation between Dr Joshua Sabari, a Medical Oncologist specialising in the treatment of rare alternations of NSCLC and Debr...
The HER2 diagnostic and treatment landscape in NSCLC
28 Apr 2025
Contributed by Lukas
Episode 2: Navigating common treatment scenarios in HER2-mutant NSCLC This is the second episode of a two-part series on the HER2 diagnostic and tre...
The HER2 Diagnostic and Treatment Landscape in NSCLC
15 Apr 2025
Contributed by Lukas
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on th...
ER+ metastatic breast cancer: Key insights on elacestrant from the latest EMERALD subgroup analyses
31 Mar 2025
Contributed by Lukas
In this podcast, Dr Aditya Bardia and Dr Virginia Kaklamani share their insights on the recent publication of the subgroup analyses from the phase 3 E...
Best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer
21 Mar 2025
Contributed by Lukas
This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer. Dr Rena Callahan and Dr...
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions
17 Feb 2025
Contributed by Lukas
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions Key clinical takeaways: MMR status should be tested...
Intermediate HCC – The evolving role of IO
20 Jan 2025
Contributed by Lukas
Intermediate HCC – The evolving role of IO In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology...
Intermediate HCC – treatment options and strategies
07 Jan 2025
Contributed by Lukas
In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Int...
HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch
03 Dec 2024
Contributed by Lukas
Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the se...
Testing to treatment of BRAF-mutant metastatic NSCLC
25 Nov 2024
Contributed by Lukas
Testing to treatment of BRAF-mutant metastatic NSCLC In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzz...
HCC podcast series part 1: The use of IO in unresectable HCC
21 Nov 2024
Contributed by Lukas
In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunother...
BRAF-mutated CRC: testing to treatment
08 Nov 2024
Contributed by Lukas
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategi...
Neuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisions
11 Sep 2024
Contributed by Lukas
In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sall...
Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey
11 Sep 2024
Contributed by Lukas
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally...
Regional differences in NET: Treatment and future developments
28 May 2024
Contributed by Lukas
In the second episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss how to optimize treatment for people livi...
Regional differences in NET: Epidemiology, diagnosis, and referral strategies
28 May 2024
Contributed by Lukas
In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology,...
Understanding the needs of different patient populations in colorectal cancer
15 May 2024
Contributed by Lukas
Do you understand the needs of different patient groups with colorectal cancer? Do you know about the barriers to treatment experienced by different...
Interpreting real-world evidence in later-line mCRC
07 May 2024
Contributed by Lukas
What are the challenges and considerations when using real-world evidence to inform your clinical practice? How can data from real-world studies be us...
Cáncer de ovario: dificultades en la fase preanalítica y pruebas de biomarcadores
25 Apr 2024
Contributed by Lukas
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante ident...
Câncer de ovário: Desafios da fase pré-analítica e teste de biomarcadores
25 Apr 2024
Contributed by Lukas
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de ovário e como podemos superá-los? Qual a importância de de...
Cáncer de próstata: dificultades en la fase preanalítica y pruebas de biomarcadores
25 Apr 2024
Contributed by Lukas
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de próstata, y cómo podemos superarlos? ¿Por qué es importante ident...
Câncer de Próstata: Desafios da Fase Pré-Analítica e Teste de Biomarcadores
25 Apr 2024
Contributed by Lukas
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de próstata e como podemos superá-los? Qual a importância de ...
Cáncer de pulmón: dificultades en la fase preanalítica y pruebas de biomarcadores
25 Apr 2024
Contributed by Lukas
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de pulmón, y cómo podemos superarlos? ¿Por qué es importante identif...
Câncer de pulmão: Desafios da fase pré-analítica e teste de biomarcadores
25 Apr 2024
Contributed by Lukas
Quais são os desafios mais comuns na fase pré-analítica na luta contra o câncer de pulmão e como podemos superá-los? Qual a importância de de...
mCRC: Optimising patient outcomes with late-line treatment
28 Mar 2024
Contributed by Lukas
What treatment options are available for patients with metastatic colorectal cancer who have already progressed through multiple lines of therapy? H...
Perseverance pays off – Looking beyond the obvious mutations in NSCLC
28 Mar 2024
Contributed by Lukas
Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tes...
Ovarian cancer: Pre-analytical phase challenges and biomarker testing
23 Feb 2024
Contributed by Lukas
What are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterat...
Lung cancer: Pre-analytical phase challenges and biomarker testing
25 Jan 2024
Contributed by Lukas
What are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alteration...
Treatment optimization in mCRC: third-line and beyond
10 Jan 2024
Contributed by Lukas
Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as p...
Precision oncology: An overview of tumour agnostic therapies
07 Dec 2023
Contributed by Lukas
What are tumour agnostic cancer treatments and which biomarkers do they target? Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Cente...
Prostate Cancer: Pre-Analytical Phase Challenges and Biomarker Testing
06 Dec 2023
Contributed by Lukas
What are the common pre-analytical phase challenges in prostate cancer, and how can we overcome them? Why is it important to identify genetic altera...
Severe PHH. Part 2 - Learnings from clinical practice
06 Dec 2023
Contributed by Lukas
In this podcast, Prof. Andra H. James (Professor Emeritus of Obstetrics and Gynecology, Division Maternal Fetal Medicine, Duke University Hospital, Du...
Managing thrombosis: Part 2 - Cancer and thrombosis
06 Dec 2023
Contributed by Lukas
In this podcast episode, Prof Dimitrios Tsakiris (Haematologist, Basel University, Switzerland) and Dr Lars Asmis (Haematologist, University of Zurich...
Advanced HCC: 2nd line treatment and the right time to switch
06 Dec 2023
Contributed by Lukas
Prof. Dr Amit Singal, Gastroenterologist and Hepatologist at UT Southwestern Medical Center, USA and Prof. Dr Jeroen Dekervel, GI Oncologist at UZ Leu...
Breast cancer: Oral SERDs in ER+ BC. Part 3 - Rare cases & treatment challenges
06 Dec 2023
Contributed by Lukas
In this final episode, the experts discuss two patient case studies with oral SERDs (oral selective estrogen receptor degraders) and a novel therapy f...
Precision oncology: An introduction to molecular testing
06 Dec 2023
Contributed by Lukas
This podcast episode provides an introduction to molecular testing in the diagnosis and treatment of cancer. Prof. David Hong from MD Anderson Cance...
Breast cancer: Oral SERDs in ER+ BC. Part 2 - Treatment selection and beyond
06 Dec 2023
Contributed by Lukas
In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment se...
Gastric and GEJ cancers: Clinical case discussions. Part 2 - metastatic disease
06 Dec 2023
Contributed by Lukas
This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford...
Gastric and GEJ cancers: Clinical case discussions. Part 1 - non-metastatic disease
06 Dec 2023
Contributed by Lukas
This podcast series consists of two episodes where expert oncologists Dr Sam Klempner (Massachusetts General Hospital, USA) and Dr Lizzy Smyth (Oxford...
Breast cancer: Oral SERDs in ER+ BC. Part 1 - Efficacy, safety and the treatment landscape
06 Dec 2023
Contributed by Lukas
In this podcast, the experts give an overview of the EMERALD trial and present elacestrant as the first, and currently only, oral SERD to be FDA a...
Prostate cancer: Treatment intensification in mCSPC - The nurse perspective
06 Dec 2023
Contributed by Lukas
In this podcast GU NURSES CONNECT members Brenda Martone and Jennifer Sutton discuss the nurse role in managing treatment intensification for metastat...
Colorectal cancer: Treatment sequencing in advanced mCRC
06 Dec 2023
Contributed by Lukas
This podcast episode discusses treatment sequencing in advanced metastatic colorectal cancer (mCRC) patients, third line and beyond. Dr Shubham Pant...
Prostate cancer: Which mCSPC patients benefit from early treatment intensification? Case-based discussion
06 Dec 2023
Contributed by Lukas
Assoc. Prof. Shilpa Gupta and Dr Fabio Schutz, discuss early treatment intensification with triplet therapy for metastatic castration-sensitive prosta...
Prostate cancer: PARP inhibitors. Part 3 - Efficacy and safety of combination therapy
06 Dec 2023
Contributed by Lukas
Dr Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr Neeraj Agarwal, Medical Oncologist and Director of the G...
Advanced HCC: Patients not eligible for IO - What are the treatment options?
06 Dec 2023
Contributed by Lukas
Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepat...
Prostate cancer: PARP inhibitors. Part 2 - Combination therapy; US and EU perspectives
06 Dec 2023
Contributed by Lukas
Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, M...
Prostate cancer: PARP inhibitors. Part 1 - PARPi monotherapy; US and EU perspectives
06 Dec 2023
Contributed by Lukas
Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, M...
Endometrial carcinoma: Systemic therapies. Part 2 - The nurses' perspective
06 Dec 2023
Contributed by Lukas
Join Lead Nurse Andreia Fernandes and Clinical Nurse Specialist Jo Pearson as they explain how to help patients navigate the side effects of systemic ...
Endometrial carcinoma: Systemic therapies. Part 1 - The physicians' perspective
06 Dec 2023
Contributed by Lukas
Join world-renowned gynaecological oncology experts Dr Domenica “Ketta” Lorusso and Dr Mansoor Mirza as they explore the changing landscape of sys...
Lower GI cancer: Highlights from ASCO GI 2023 - Part 2
06 Dec 2023
Contributed by Lukas
This episode, covers the highlights on colorectal cancer from ASCO GI 2023. Prof. Andrea Sartore-Bianchi (Niguada Cancer Center, Milan, Italy) and P...
Upper GI cancer Highlights from ASCO GI 2023 - Part 1
06 Dec 2023
Contributed by Lukas
This episode, covers the highlights on gastroesophageal, gastric and gastroesophageal junction (GEJ) cancer from ASCO GI 2023. Dr Nataliya Uboha (Un...
Sarcoma: Updates from CTOS 2022
06 Dec 2023
Contributed by Lukas
In this podcast, Prof. Jonathan Trent and Prof. Robin Jones discuss what’s new in the patient management in sarcoma from CTOS 2022. The Connective T...
Advanced RCC: Clinical implementation of targeted therapies and immunotherapies
06 Dec 2023
Contributed by Lukas
Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Dr Friederike Schlürmann a Medical Oncologist from University Hospit...
Neuroendocrine tumours: The role of SSA at progression - To continue or not?
06 Dec 2023
Contributed by Lukas
In this podcast, Prof. Martyn Caplin and Dr Aman Chauhan discuss the role of somatostatin analogues (SSAs) at progression and whether to continue or n...
HCC: Updates from ILCA and ESMO 2022
06 Dec 2023
Contributed by Lukas
In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of new HCC Phase...
Upper GI cancer: Update from ESMO 2022 - Part 2
06 Dec 2023
Contributed by Lukas
This second GI CONNECT podcast episode, covers the highlights on gastroesophageal cancer from ESMO 2022. Dr Sam Klempner (Massachusetts General Hosp...
Lower GI cancer: Update from ESMO 2022 - Part 1
06 Dec 2023
Contributed by Lukas
In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny Seligmann, Medical...
Colorectal cancer: Flexible dosing of oral treatments in mCRC
06 Dec 2023
Contributed by Lukas
In this podcast, Sven De Keersmaecker, RN and Assoc. Prof. Gerald Prager, MD discuss flexible dosing regimens of the oral treatments regorafenib, trif...
Sarcoma: Updated bone sarcoma guidelines - Clinical implications
06 Dec 2023
Contributed by Lukas
In this SARCOMA CONNECT Guidelines Podcast, two SARCOMA CONNECT Experts, Prof. Robert Maki and Prof. Silvia Stacchiotti, discuss recent updates in t...
HCC: The role of immunotherapy beyond advanced HCC
06 Dec 2023
Contributed by Lukas
In this podcast, liver cancer experts Prof. Amit Singal and Assoc. Prof Neil Mehta discuss recent advances in systemic and locoregional therapy for ad...
Prostate cancer: Highlights from ASCO GU, ASCO and EAUN 2022
06 Dec 2023
Contributed by Lukas
In this podcast Dr Jason Alcorn and Jennifer Sutton discuss the oncology nursing highlights from ASCO GU, ASCO and EAUN 2022. The experts discuss: ...
Prostate cancer: Shared decision-making in nmCRPC
06 Dec 2023
Contributed by Lukas
Brenda Martone, a nurse practitioner at Northwestern Medicine in Chicago Illinois and Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-...
Prostate cancer: Timing of ARSI and taxanes in mCSPC
06 Dec 2023
Contributed by Lukas
Dr. Tanya Dorff, a Medical Oncologist from the City of Hope Comprehensive Cancer Center and Dr. Neal Shore, Uro-Oncologist and Chief Medical Officer f...
GI cancer: Management of skin toxicity from multikinase inhibitors
06 Dec 2023
Contributed by Lukas
In this podcast, Beth Wittmer RN, Director of Care Management at Florida Cancer Specialists, USA and Prof. Hans Prenen, GI Medical Oncologist from Ant...
Multiple Myeloma: Choosing the best treatment regimen in patients with high-risk cytogenetics - Part 3
06 Dec 2023
Contributed by Lukas
In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Leso...
Prostate cancer: Highlights from ASCO GU 2022
06 Dec 2023
Contributed by Lukas
COR2ED Medical Education: Dr Alicia Morgans, Genitourinary Medical Oncologist at the Dana-Farber Cancer Institute in the United States and Dr. Neal Sh...
HCC: Key topics discussed at ASCO GI & EASL 2022
06 Dec 2023
Contributed by Lukas
Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics d...
Prostate cancer: PARP inhibitors in prostate cancer
06 Dec 2023
Contributed by Lukas
COR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom ...
Cáncer de próstata: Inhibidores de PARP - lo que las enfermeras necesitan saber
06 Dec 2023
Contributed by Lukas
COR2ED Educación Médica: Pablo Peinado, coordinador de Enfermería de Investigación, y la Dra. Elena Castro, oncóloga médica, quienes trabajan en...
Prostate cancer: PARP inhibitors in prostate cancer - What nurses need to know
06 Dec 2023
Contributed by Lukas
COR2ED Medical Education: Pablo Peinado, Research Nurse Coordinator, and Dr. Elena Castro, medical oncologist, who both work at Hospital Universitario...
Prostate cancer: Genetic testing and PARP inhibitors in prostate cancer
06 Dec 2023
Contributed by Lukas
COR2ED Medical Education: Joanne Chien, Nurse Practitioner specialising in urologic cancers at Stanford Health Care in Palo Alto, California, and Dr A...
Precision oncology: Detection and treatment of TRK fusion-positive lung cancers
06 Dec 2023
Contributed by Lukas
In this medical education podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center ...
HCC: VEGFR-TKIs alone or in combination with immune checkpoint inhibitors
06 Dec 2023
Contributed by Lukas
In this medical education podcast episode, Prof. Peter Galle and Prof. Amit Singal discuss the use of VEGFR-TKIs in the treatment of advanced or unres...
RCC: Treating advanced RCC - The role of VEGFR-TKIs alone or in combination therapy
06 Dec 2023
Contributed by Lukas
Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of Graz...
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 3 - Future developments
06 Dec 2023
Contributed by Lukas
In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Ch...
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 2 - Immunotherapy
06 Dec 2023
Contributed by Lukas
In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Ch...
Colorectal and gastric cancer: Current and future therapeutic approaches. Part 1 - Targeted therapy
06 Dec 2023
Contributed by Lukas
In this podcast series, Dr. Jenny Seligmann (University of Leeds, UK), Dr. Autumn McRee (University of North Carolina, USA) and Dr. Dominik Modest (Ch...
Multiple Myeloma: Choosing the best treatment regimen in patients with relapsed/refractory MM - Part 2
06 Dec 2023
Contributed by Lukas
In this medical education podcast series, myeloma experts Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford Uni...
HCC: VEGFR-TKI monotherapy for unresectable or advanced HCC in 1st line setting
06 Dec 2023
Contributed by Lukas
Prof. Josep Llovet and Prof. Stephen L. Chan discuss a very interesting topic about the use of the VEGFR TKIs monotherapy in the treatment of unresect...
Multiple Myeloma: Choosing the best treatment regimen in newly diagnosed patients - Part 1
06 Dec 2023
Contributed by Lukas
In this medical education podcast series, myeloma experts Dr. Joshua Richter (Assistant Professor of Medicine and Director of Myeloma at the Tisch Can...
HCC: Highlights from ILCA and ESMO 2021
06 Dec 2023
Contributed by Lukas
Professor Matthias Pinter, medical hepatologist from the medical University of Vienna in Austria shares some insights from key abstracts and topics di...
Precision oncology: Diagnosis and treatment of TRK fusion-positive GI cancers
06 Dec 2023
Contributed by Lukas
In this podcast, PO CONNECT members Prof Frédérique Penault-Llorca (University of Clermont-Ferrand, France) and Prof Andrea Sartore-Bianchi (Niguard...
VEGFR-TKIs: Nurse management of adverse events
06 Dec 2023
Contributed by Lukas
In this podcast, Veerle Lamotte, an oncology nurse practitioner at Antwerp University Hospital and Paola Belardi, nurse chief at San Donato Hospital ...
Thyroid cancer: Optimising VEGFR-TKIs (MKIs) in differentiated thyroid cancer
06 Dec 2023
Contributed by Lukas
Dr. Jaume Capdevila, a Medical Oncologist at Vall d’Hebron University Hospital in Barcelona, Spain, and Dr. Rachel van Leeuwaarde, an Endocrinologis...
HCC: Highlights from ASCO and WCGIC 2021
06 Dec 2023
Contributed by Lukas
In this episode, Dr Choo discusses some key abstracts presented during the virtual ASCO and WCGIC congresses in 2021. Dr Choo comments that despite ...
Prostate cancer: Radiopharmaceuticals. Part 2 - PSMA theranostics
06 Dec 2023
Contributed by Lukas
Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) disc...
Prostate cancer: Radiopharmaceuticals. Part 1 - Radium-223
06 Dec 2023
Contributed by Lukas
Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) disc...